Skip to main content
Top
Published in: Respiratory Research 1/2022

Open Access 01-12-2022 | Sarcopenia | Research

Identification of factors impairing exercise capacity after severe COVID-19 pulmonary infection: a 3-month follow-up of prospective COVulnerability cohort

Authors: Bruno Ribeiro Baptista, Thomas d’Humières, Frédéric Schlemmer, Inès Bendib, Grégoire Justeau, Lara Al-Assaad, Mouna Hachem, Rebecca Codiat, Benjamin Bardel, Laure Abou Chakra, Thibaut Belmondo, Etienne Audureau, Sophie Hue, Armand Mekontso-Dessap, Geneviève Derumeaux, Laurent Boyer

Published in: Respiratory Research | Issue 1/2022

Login to get access

Abstract

Background

Patient hospitalized for coronavirus disease 2019 (COVID-19) pulmonary infection can have sequelae such as impaired exercise capacity. We aimed to determine the frequency of long-term exercise capacity limitation in survivors of severe COVID-19 pulmonary infection and the factors associated with this limitation.

Methods

Patients with severe COVID-19 pulmonary infection were enrolled 3 months after hospital discharge in COVulnerability, a prospective cohort. They underwent cardiopulmonary exercise testing, pulmonary function test, echocardiography, and skeletal muscle mass evaluation.

Results

Among 105 patients included, 35% had a reduced exercise capacity (VO2peak < 80% of predicted). Compared to patients with a normal exercise capacity, patients with reduced exercise capacity were more often men (89.2% vs. 67.6%, p = 0.015), with diabetes (45.9% vs. 17.6%, p = 0.002) and renal dysfunction (21.6% vs. 17.6%, p = 0.006), but did not differ in terms of initial acute disease severity. An altered exercise capacity was associated with an impaired respiratory function as assessed by a decrease in forced vital capacity (p < 0.0001), FEV1 (p < 0.0001), total lung capacity (p < 0.0001) and DLCO (p = 0.015). Moreover, we uncovered a decrease of muscular mass index and grip test in the reduced exercise capacity group (p = 0.001 and p = 0.047 respectively), whilst 38.9% of patients with low exercise capacity had a sarcopenia, compared to 10.9% in those with normal exercise capacity (p = 0.001). Myocardial function was normal with similar systolic and diastolic parameters between groups whilst reduced exercise capacity was associated with a slightly shorter pulmonary acceleration time, despite no pulmonary hypertension.

Conclusion

Three months after a severe COVID-19 pulmonary infection, more than one third of patients had an impairment of exercise capacity which was associated with a reduced pulmonary function, a reduced skeletal muscle mass and function but without any significant impairment in cardiac function.
Appendix
Available only for authorised users
Literature
1.
go back to reference Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRef Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497–506.CrossRef
2.
go back to reference Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.PubMedPubMedCentral Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020;395(10223):507–13.PubMedPubMedCentral
3.
go back to reference Huang Y, Tan C, Wu J, Chen M, Wang Z, Luo L, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21(1):163.CrossRef Huang Y, Tan C, Wu J, Chen M, Wang Z, Luo L, et al. Impact of coronavirus disease 2019 on pulmonary function in early convalescence phase. Respir Res. 2020;21(1):163.CrossRef
4.
go back to reference Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60(5):401–9.CrossRef Hui DS, Joynt GM, Wong KT, Gomersall CD, Li TS, Antonio G, et al. Impact of severe acute respiratory syndrome (SARS) on pulmonary function, functional capacity and quality of life in a cohort of survivors. Thorax. 2005;60(5):401–9.CrossRef
5.
go back to reference Ngai JC, Ko FW, Ng SS, To K-W, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010;15(3):543–50.CrossRef Ngai JC, Ko FW, Ng SS, To K-W, Tong M, Hui DS. The long-term impact of severe acute respiratory syndrome on pulmonary function, exercise capacity and health status. Respirology. 2010;15(3):543–50.CrossRef
6.
go back to reference Park WB, Jun KI, Kim G, Choi J-P, Rhee J-Y, Cheon S, et al. Correlation between pneumonia severity and pulmonary complications in middle east respiratory syndrome. J Korean Med Sci. 2018;33(24): e169.CrossRef Park WB, Jun KI, Kim G, Choi J-P, Rhee J-Y, Cheon S, et al. Correlation between pneumonia severity and pulmonary complications in middle east respiratory syndrome. J Korean Med Sci. 2018;33(24): e169.CrossRef
7.
go back to reference Frija-Masson J, Debray M-P, Gilbert M, Lescure F-X, Travert F, Borie R, et al. Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection. Eur Respir J. 2020;56(2):2001754.CrossRef Frija-Masson J, Debray M-P, Gilbert M, Lescure F-X, Travert F, Borie R, et al. Functional characteristics of patients with SARS-CoV-2 pneumonia at 30 days post-infection. Eur Respir J. 2020;56(2):2001754.CrossRef
8.
go back to reference Noel-Savina E, Viatgé T, Faviez G, Lepage B, Mhanna LT, Pontier S, et al. Severe SARS-CoV-2 pneumonia: clinical, functional and imaging outcomes at 4 months. Respir Med Res. 2021;80: 100822.PubMedPubMedCentral Noel-Savina E, Viatgé T, Faviez G, Lepage B, Mhanna LT, Pontier S, et al. Severe SARS-CoV-2 pneumonia: clinical, functional and imaging outcomes at 4 months. Respir Med Res. 2021;80: 100822.PubMedPubMedCentral
9.
go back to reference Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-Month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9(7):747–54.CrossRef Wu X, Liu X, Zhou Y, Yu H, Li R, Zhan Q, et al. 3-Month, 6-month, 9-month, and 12-month respiratory outcomes in patients following COVID-19-related hospitalisation: a prospective study. Lancet Respir Med. 2021;9(7):747–54.CrossRef
10.
go back to reference Skjørten I, Ankerstjerne OAW, Trebinjac D, Brønstad E, Rasch-Halvorsen Ø, Einvik G, et al. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. Eur Respir J. 2021;58(2):2100996.CrossRef Skjørten I, Ankerstjerne OAW, Trebinjac D, Brønstad E, Rasch-Halvorsen Ø, Einvik G, et al. Cardiopulmonary exercise capacity and limitations 3 months after COVID-19 hospitalisation. Eur Respir J. 2021;58(2):2100996.CrossRef
11.
go back to reference Rinaldo RF, Mondoni M, Parazzini EM, Pitari F, Brambilla E, Luraschi S, et al. Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors. Eur Respir J. 2021;58(2):2100870.CrossRef Rinaldo RF, Mondoni M, Parazzini EM, Pitari F, Brambilla E, Luraschi S, et al. Deconditioning as main mechanism of impaired exercise response in COVID-19 survivors. Eur Respir J. 2021;58(2):2100870.CrossRef
12.
go back to reference Gandhi RT, Lynch JB, del Rio C. Mild or moderate COVID-19. N Engl J Med. 2020;383(18):1757–66.CrossRef Gandhi RT, Lynch JB, del Rio C. Mild or moderate COVID-19. N Engl J Med. 2020;383(18):1757–66.CrossRef
13.
go back to reference Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755–63.CrossRef Baumgartner RN, Koehler KM, Gallagher D, Romero L, Heymsfield SB, Ross RR, et al. Epidemiology of sarcopenia among the elderly in New Mexico. Am J Epidemiol. 1998;147(8):755–63.CrossRef
14.
go back to reference Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. Eur Respir J. 1997;10(11):2662–89 Clinical exercise testing with reference to lung diseases: indications, standardization and interpretation strategies. Eur Respir J. 1997;10(11):2662–89
15.
go back to reference Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. Eur Respir J. 1993;6(Suppl 16):5–40.CrossRef Quanjer PH, Tammeling GJ, Cotes JE, Pedersen OF, Peslin R, Yernault J-C. Lung volumes and forced ventilatory flows. Eur Respir J. 1993;6(Suppl 16):5–40.CrossRef
16.
go back to reference Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.CrossRef Quanjer PH, Stanojevic S, Cole TJ, Baur X, Hall GL, Culver BH, et al. Multi-ethnic reference values for spirometry for the 3–95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–43.CrossRef
17.
go back to reference Nagueh SF, Abraham TP, Aurigemma GP, Bax JJ, Beladan C, Browning A, et al. Interobserver variability in applying American Society of Echocardiography/European Association of Cardiovascular Imaging 2016 guidelines for estimation of left ventricular filling pressure. Circ Cardiovasc Imaging. 2019;12(1): e008122.CrossRef Nagueh SF, Abraham TP, Aurigemma GP, Bax JJ, Beladan C, Browning A, et al. Interobserver variability in applying American Society of Echocardiography/European Association of Cardiovascular Imaging 2016 guidelines for estimation of left ventricular filling pressure. Circ Cardiovasc Imaging. 2019;12(1): e008122.CrossRef
18.
go back to reference Ernande L, Cottin V, Leroux P-Y, Girerd N, Huez S, Mulliez A, et al. Right isovolumic contraction velocity predicts survival in pulmonary hypertension. J Am Soc Echocardiogr. 2013;26(3):297–306.CrossRef Ernande L, Cottin V, Leroux P-Y, Girerd N, Huez S, Mulliez A, et al. Right isovolumic contraction velocity predicts survival in pulmonary hypertension. J Am Soc Echocardiogr. 2013;26(3):297–306.CrossRef
19.
go back to reference Bai C, Chotirmall SH, Rello J, Alba GA, Ginns LC, Krishnan JA, et al. Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force. Eur Respir Rev. 2020;29(157). Bai C, Chotirmall SH, Rello J, Alba GA, Ginns LC, Krishnan JA, et al. Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force. Eur Respir Rev. 2020;29(157).
20.
go back to reference Su M-C, Hsieh Y-T, Wang Y-H, Lin A-S, Chung Y-H, Lin M-C. exercise capacity and pulmonary function in hospital workers recovered from severe acute respiratory syndrome. Respiration. 2007;74(5):511–6.CrossRef Su M-C, Hsieh Y-T, Wang Y-H, Lin A-S, Chung Y-H, Lin M-C. exercise capacity and pulmonary function in hospital workers recovered from severe acute respiratory syndrome. Respiration. 2007;74(5):511–6.CrossRef
21.
go back to reference Ong K-C, Ng AW-K, Lee LS-U, Kaw G, Kwek S-K, Leow MK-S, et al. Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome. Eur Respir J. 2004;24(3):436–42.CrossRef Ong K-C, Ng AW-K, Lee LS-U, Kaw G, Kwek S-K, Leow MK-S, et al. Pulmonary function and exercise capacity in survivors of severe acute respiratory syndrome. Eur Respir J. 2004;24(3):436–42.CrossRef
22.
go back to reference Motiejunaite J, Balagny P, Arnoult F, Mangin L, Bancal C, Vidal-Petiot E, et al. Hyperventilation as one of the mechanisms of persistent dyspnea in SARS-CoV-2 survivors. Eur Respir J. 2021;58(2):2101578.CrossRef Motiejunaite J, Balagny P, Arnoult F, Mangin L, Bancal C, Vidal-Petiot E, et al. Hyperventilation as one of the mechanisms of persistent dyspnea in SARS-CoV-2 survivors. Eur Respir J. 2021;58(2):2101578.CrossRef
23.
go back to reference Haykowsky MJ, Kouba EJ, Brubaker PH, Nicklas BJ, Eggebeen J, Kitzman DW. Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol. 2014;113(7):1211–6.CrossRef Haykowsky MJ, Kouba EJ, Brubaker PH, Nicklas BJ, Eggebeen J, Kitzman DW. Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol. 2014;113(7):1211–6.CrossRef
24.
go back to reference Broxterman RM, Hoff J, Wagner PD, Richardson RS. Determinants of the diminished exercise capacity in patients with chronic obstructive pulmonary disease: looking beyond the lungs. J Physiol. 2020;598(3):599–610.CrossRef Broxterman RM, Hoff J, Wagner PD, Richardson RS. Determinants of the diminished exercise capacity in patients with chronic obstructive pulmonary disease: looking beyond the lungs. J Physiol. 2020;598(3):599–610.CrossRef
25.
go back to reference Curcio F, Testa G, Liguori I, Papillo M, Flocco V, Panicara V, et al. Sarcopenia and heart failure. Nutrients. 2020;12(1):211.CrossRef Curcio F, Testa G, Liguori I, Papillo M, Flocco V, Panicara V, et al. Sarcopenia and heart failure. Nutrients. 2020;12(1):211.CrossRef
26.
go back to reference Sepúlveda-Loyola W, Osadnik C, Phu S, Morita AA, Duque G, Probst VS. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2020;11(5):1164–76.CrossRef Sepúlveda-Loyola W, Osadnik C, Phu S, Morita AA, Duque G, Probst VS. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle. 2020;11(5):1164–76.CrossRef
27.
go back to reference Boyer L, Chouaïd C, Bastuji-Garin S, Marcos E, Margarit L, Le Corvoisier P, et al. Aging-related systemic manifestations in COPD patients and cigarette smokers. PLoS ONE. 2015;10(3): e0121539.CrossRef Boyer L, Chouaïd C, Bastuji-Garin S, Marcos E, Margarit L, Le Corvoisier P, et al. Aging-related systemic manifestations in COPD patients and cigarette smokers. PLoS ONE. 2015;10(3): e0121539.CrossRef
28.
go back to reference Caci G, Albini A, Malerba M, Noonan DM, Pochetti P, Polosa R. COVID-19 and obesity: dangerous liaisons. J Clin Med. 2020;9(8):2511.CrossRef Caci G, Albini A, Malerba M, Noonan DM, Pochetti P, Polosa R. COVID-19 and obesity: dangerous liaisons. J Clin Med. 2020;9(8):2511.CrossRef
29.
go back to reference Huang Y, Lu Y, Huang Y-M, Wang M, Ling W, Sui Y, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism. 2020;113: 154378.CrossRef Huang Y, Lu Y, Huang Y-M, Wang M, Ling W, Sui Y, et al. Obesity in patients with COVID-19: a systematic review and meta-analysis. Metabolism. 2020;113: 154378.CrossRef
30.
go back to reference Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B, et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J. 2021;57(4):2003481.CrossRef Sonnweber T, Sahanic S, Pizzini A, Luger A, Schwabl C, Sonnweber B, et al. Cardiopulmonary recovery after COVID-19: an observational prospective multicentre trial. Eur Respir J. 2021;57(4):2003481.CrossRef
31.
go back to reference Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, Solis-Navarro L, Burgos F, Puppo H, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2021;27(4):328–37.CrossRef Torres-Castro R, Vasconcello-Castillo L, Alsina-Restoy X, Solis-Navarro L, Burgos F, Puppo H, et al. Respiratory function in patients post-infection by COVID-19: a systematic review and meta-analysis. Pulmonology. 2021;27(4):328–37.CrossRef
32.
go back to reference Zhu J, Pang J, Ji P, Zhong Z, Li H, Li B, et al. Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis. J Med Virol. 2021;93(1):35–7.CrossRef Zhu J, Pang J, Ji P, Zhong Z, Li H, Li B, et al. Elevated interleukin-6 is associated with severity of COVID-19: A meta-analysis. J Med Virol. 2021;93(1):35–7.CrossRef
33.
go back to reference Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, et al. Association of elevated inflammatory markers and severe COVID-19: a meta-analysis. Medicine (Baltimore). 2020;99(47): e23315.CrossRef Ji P, Zhu J, Zhong Z, Li H, Pang J, Li B, et al. Association of elevated inflammatory markers and severe COVID-19: a meta-analysis. Medicine (Baltimore). 2020;99(47): e23315.CrossRef
34.
go back to reference Tuttle CSL, Thang LAN, Maier AB. Markers of inflammation and their association with muscle strength and mass: a systematic review and meta-analysis. Ageing Res Rev. 2020;64: 101185.CrossRef Tuttle CSL, Thang LAN, Maier AB. Markers of inflammation and their association with muscle strength and mass: a systematic review and meta-analysis. Ageing Res Rev. 2020;64: 101185.CrossRef
35.
go back to reference Byun MK, Cho EN, Chang J, Ahn CM, Kim HJ. Sarcopenia correlates with systemic inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:669–75.CrossRef Byun MK, Cho EN, Chang J, Ahn CM, Kim HJ. Sarcopenia correlates with systemic inflammation in COPD. Int J Chron Obstruct Pulmon Dis. 2017;12:669–75.CrossRef
36.
go back to reference Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–43.CrossRef Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, et al. An inflammatory cytokine signature predicts COVID-19 severity and survival. Nat Med. 2020;26(10):1636–43.CrossRef
Metadata
Title
Identification of factors impairing exercise capacity after severe COVID-19 pulmonary infection: a 3-month follow-up of prospective COVulnerability cohort
Authors
Bruno Ribeiro Baptista
Thomas d’Humières
Frédéric Schlemmer
Inès Bendib
Grégoire Justeau
Lara Al-Assaad
Mouna Hachem
Rebecca Codiat
Benjamin Bardel
Laure Abou Chakra
Thibaut Belmondo
Etienne Audureau
Sophie Hue
Armand Mekontso-Dessap
Geneviève Derumeaux
Laurent Boyer
Publication date
01-12-2022
Publisher
BioMed Central
Published in
Respiratory Research / Issue 1/2022
Electronic ISSN: 1465-993X
DOI
https://doi.org/10.1186/s12931-022-01977-z

Other articles of this Issue 1/2022

Respiratory Research 1/2022 Go to the issue